



City of Cambridge

R-72.

IN CITY COUNCIL

March 19, 2001

COUNCILLOR SULLIVAN
COUNCILLOR BORN
COUNCILLOR DAVIS
COUNCILLOR DECKER
MAYOR GALLUCCIO
VICE MAYOR MAHER
COUNCILLOR REEVES
COUNCILLOR TOOMEY

WHEREAS: Transkaryotic Therapies Inc. (TKT), a Cambridge biotech company, received a US patent for the treatment of a genetic disorder; and

WHEREAS: Sanfilippo Syndrome Type A is a genetic disorder that leads to skeletal deformities and progressive mental retardation; now therefore be it

RESOLVED: That the City Council go on record extending its congratulations to Transkaryotic Therapies Inc. on receiving this patent; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Transkaryotic Therapies Inc. on behalf of the entire City Council.

In City Council March 19, 2001.

Adopted by the affirmative vote of eight members.

Attest:- D. Margaret Drury, City Clerk.

A true copy;

ATTEST:-

A handwritten signature in cursive script, reading "D. Margaret Drury".

D. Margaret Drury
City Clerk

CC

3/15 @ 7:40 @

R-72
CC

MS

yes lms per

no ?

TKT of pattern drug

Cornell Sullivan

Whereas: TransKaryotic Therapies, INC (TKT) ^{a Cambiotech company} received a US patent for the treatment of a genetic disorder; &

whereas SanFilippo Syndrome type A is a genetic disorder that leads to skeletal deformities & progressive mental retardation; now therefore be it

Resolved That the City Council go on record extending its congratulations to TKT on receiving this patent; & be it further

Res SEC to TKT

TKT wins patent

Transkaryotic Therapies Inc. said it received a US patent for the treatment of Sanfilippo Syndrome Type A, a rare inherited genetic disorder that leads to skeletal deformities and progressive mental retardation. The Cambridge company said the patent was issued to Women and Children's Hospital in North Adelaide, Australia and licensed to TKT.

The Cambridge company said Australian researchers have cloned the gene and DNA for sulphamidase, a protein missing in patients with the disease.

NAOMI AOKI
AND RONALD ROSENBERG



City of Cambridge

R-72.

IN CITY COUNCIL

March 19, 2001

COUNCILLOR SULLIVAN

WHEREAS: Transkaryotic Therapies Inc. (TKT), a Cambridge biotech company, received a US patent for the treatment of a genetic disorder; and

WHEREAS: Sanfilippo Syndrome Type A is a genetic disorder that leads to skeletal deformities and progressive mental retardation; now therefore be it

RESOLVED: That the City Council go on record extending its congratulations to Transkaryotic Therapies Inc. on receiving this patent; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to Transkaryotic Therapies Inc. on behalf of the entire City Council.

401R

Resolution #72

Congratulations to Transkaryotic
Therapies Inc. on the receipt of a
US patent for the treatment of a
genetic disorder.

Councillor Sullivan

In City Council March 19, 2001

ORDER ADOPTED